

Putting NICE guidance into practice

Costing statement: Lung cancer - afatinib

Implementing the NICE guidance on Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)

Published: April 2014

NHS England commissions this technology as part of specialised cancer services.

Because afatinib is available with a patient access scheme it is not expected that the cost of treatment will be significantly different from that of current standard treatments. Therefore it is unlikely that the guidance will result in a significant change in resource use in the NHS. Afatinib is an additional treatment option alongside current standard treatment options erlotinib and gefatinib which are both available with a patient access scheme. The population eligible for treatment is approximately 450 per year in England.

The Department of Health and the manufacturer have agreed that afatinib will be available to the NHS with a patient access scheme which makes afatinib available with a discount. The size of the discount is commercial in confidence. It is the responsibility of the manufacturer to communicate details of the discount to the relevant NHS organisations. Any enquiries from NHS organisations about the patient access scheme should be directed to onccommercial.bra@boehringer-ingenelheim.com.